Zetia Cost in North Dakota 2026: Prices, Medicaid, and How to Pay Less

What Ezetimibe Actually Does and Why Doctors Prescribe It

Ezetimibe 10 mg once daily lowers LDL cholesterol by 15 to 20 percent through selective inhibition of the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine. It works through a mechanism entirely different from statins, so the two drugs are routinely combined. The FDA approved the original Zetia brand in 2002 for primary hypercholesterolemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia. [1]

The landmark IMPROVE-IT trial enrolled 18,144 patients with recent acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At seven years, the combination arm reduced major adverse cardiovascular events by an absolute 2 percentage points (32.7% vs. 34.7%, HR 0.936, P<0.001). [2] That trial established ezetimibe as a clinically meaningful add-on therapy, not merely a lipid number tweak.

The American College of Cardiology and American Heart Association 2019 guideline on cholesterol states: "In patients with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy, it is reasonable to add ezetimibe to further reduce LDL-C." [3] For patients who cannot tolerate statins at any dose, ezetimibe monotherapy can reduce LDL by a clinically meaningful margin, typically 15 to 22 percent. [4]

Generic ezetimibe entered the U.S. market in December 2016 after Merck's exclusivity expired, and by 2018 generics represented the dominant dispensed form. [5] That patent expiration is the single biggest reason cash prices in North Dakota now sit near $15 per month rather than the $380 brand list price.

Ezetimibe Cash Prices at North Dakota Pharmacies in 2026

Generic ezetimibe 10 mg, 30-tablet supply costs approximately $15 per month at retail pharmacies across North Dakota in 2026. That figure reflects the cash-pay price after applying a free GoodRx or similar discount coupon at chains including Walmart, Walgreens, Sanford Health pharmacies in Fargo and Bismarck, and independent community pharmacies across the state.

Brand-name Zetia carries a manufacturer list price near $380 per month. Almost no cash-paying patient in North Dakota should pay that price, because the generic is therapeutically identical. The FDA's Orange Book confirms bioequivalence of all approved generic ezetimibe formulations. [5]

Prices vary by pharmacy. At the time of writing, GoodRx shows generic ezetimibe 10 mg ranging from $11 to $22 depending on the specific North Dakota pharmacy and whether you use a discount card. Costco Pharmacy in Bismarck has historically offered one of the lowest cash prices. Calling ahead to compare prices takes about five minutes and can save you several dollars each month.

Mail-order 90-day supplies through PBM-affiliated pharmacies such as Express Scripts or CVS Caremark generally reduce the per-tablet cost by an additional 10 to 15 percent on commercial insurance plans. For cash-pay patients, some mail-order programs offer 90 tablets for $30 to $35 when combined with a prescription discount card. [6]

Does North Dakota Medicaid Cover Zetia or Generic Ezetimibe?

North Dakota Medicaid does not cover Zetia (brand or generic ezetimibe) for hyperlipidemia adjunct therapy as of the current preferred drug list. This means enrolled members who need ezetimibe must either pay cash or seek a prior authorization exception, which is rarely granted without documented statin intolerance or a specific cardiovascular diagnosis pathway. [7]

North Dakota Medicaid's preferred drug list prioritizes generic statins (atorvastatin, rosuvastatin, simvastatin) as the first-line agents for hypercholesterolemia. Ezetimibe alone or combined with a statin (Vytorin) sits in a non-preferred or non-covered tier. Members should contact ND Medicaid at 1-800-755-2604 to request a step-therapy exception or prior authorization if a physician documents medical necessity.

The Centers for Medicare and Medicaid Services guidance on Part D formularies notes that plans must cover at least two drugs per therapeutic class, but the class definition used by most Part D plans groups ezetimibe separately from statins, allowing plans to restrict it. [8] Medicare Part D beneficiaries in North Dakota should check their specific plan's formulary at medicare.gov; several Part D plans do list generic ezetimibe on Tier 2 or Tier 3.

Patients under 65 who receive coverage through the North Dakota Indian Affairs Commission health programs or through tribal health facilities affiliated with the Indian Health Service should inquire directly with their facility pharmacist, as formularies differ from state Medicaid.

Insurance Coverage for Zetia in North Dakota: Tiers and Prior Authorization

Most commercial insurance plans sold through the North Dakota Blue Cross Blue Shield marketplace and employer-sponsored plans cover generic ezetimibe, but at widely varying tiers. Tier placement determines your copay.

A practical breakdown by plan type:

Tier 1 (preferred generic): Monthly copay of $0 to $10. Rare for ezetimibe in 2026, but some high-value employer plans have moved it here because the drug is off-patent and inexpensive to procure.

Tier 2 (non-preferred generic): Monthly copay of $15 to $45. This is the most common tier placement for generic ezetimibe on North Dakota commercial plans in 2026.

Tier 3 (preferred brand): Brand-name Zetia sits here on plans that still list it. Copay of $40 to $80 per month. Patients should almost always ask their prescriber to specify "generic ezetimibe" to drop to Tier 2.

Non-formulary / Tier 4 or 5: Some narrow-network plans exclude ezetimibe entirely unless a prior authorization documents failure of statin monotherapy to reach LDL goals. The ACC/AHA 2019 cholesterol guideline supports the clinical argument for this exception. [3]

Sanford Health Plan and Blue Cross Blue Shield of North Dakota both publicly list their formularies online. Reviewing your plan's Evidence of Coverage document, specifically the section on cardiovascular or lipid-lowering agents, will tell you exactly which tier your ezetimibe fills on. [9]

The Merck patient savings card for brand Zetia reduces the brand copay to as low as $5 per month for commercially insured patients, but it cannot be used by Medicaid, Medicare, or government-funded plan enrollees. Given that generic ezetimibe costs $15 cash, the brand savings card only makes sense if your plan's formulary forces brand-name Zetia for some structural reason. Merck's savings card program is accessible at merck.com/patient/savings. [10]

Compounded Ezetimibe in North Dakota: Is It Legal?

Compounded ezetimibe through a state-licensed 503A pharmacy is legal in North Dakota. Patients in the state can receive a prescription for compounded ezetimibe prepared by a licensed 503A compounding pharmacy, provided a valid prescriber-patient relationship exists and the pharmacy complies with North Dakota Board of Pharmacy regulations and federal USP standards. [11]

The legal framework matters. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare a drug for an individual patient based on a valid prescription, even if an FDA-approved commercial version exists. North Dakota follows this federal framework without imposing additional blanket bans on specific drug categories. [12]

The practical cost implication is significant. Some telehealth and direct-care programs that work with 503A pharmacies in North Dakota price compounded ezetimibe at $0 per month for enrolled patients. This is typically possible because programs bundle the drug cost into a membership or consultation fee, or because the pharmacy's compounding cost for a simple oral tablet is very low. Patients should verify that the 503A pharmacy holds current North Dakota licensure by checking the ND Board of Pharmacy's license lookup at ndhealth.gov/pharmacy. [13]

One clinical note: compounded ezetimibe is not FDA-approved and has not been subject to the same bioequivalence testing as commercially manufactured generics. Prescribers and patients should weigh this against the cost difference. For most patients, the $15 cash price of the commercial generic is low enough that compounding adds little financial advantage unless it is truly $0 through a bundled program.

Can You Get Ezetimibe via Telehealth in North Dakota?

Telehealth prescribing of ezetimibe is permitted in North Dakota. A licensed physician, nurse practitioner, or physician assistant operating under North Dakota licensure may prescribe ezetimibe through a synchronous telemedicine visit (video or phone) provided that a clinically appropriate evaluation is conducted. [14]

North Dakota follows the Interstate Medical Licensure Compact, which allows physicians licensed in a compact-member state to more easily obtain North Dakota licensure. For patients, this means telehealth platforms that hold or can obtain North Dakota prescriber credentials may serve ND residents. [15]

A standard telehealth lipid management visit would include a review of the patient's lipid panel (typically LDL-C, HDL-C, triglycerides, total cholesterol), cardiovascular risk factors, and current medications. Ezetimibe does not require DEA scheduling, so it faces none of the telemedicine controlled-substance restrictions that apply to medications like testosterone or stimulants. The prescriber simply needs to be licensed in North Dakota.

The HealthRX telehealth platform can evaluate North Dakota residents for ezetimibe therapy. A provider reviews your labs and medical history, discusses whether ezetimibe makes sense given your LDL-C target and cardiovascular risk score, and sends a prescription to your preferred pharmacy or to a partnered 503A compounding pharmacy if that is the lower-cost path for your situation.

LDL-C Goals That Justify Ezetimibe: Who Actually Needs It

Not every patient with elevated LDL needs ezetimibe. The ACC/AHA 2019 guideline defines the patients most likely to benefit. [3]

Patients with established ASCVD (prior MI, stroke, or peripheral arterial disease) and an LDL-C above 70 mg/dL despite maximally tolerated statin therapy are the clearest candidates. The IMPROVE-IT trial showed that adding ezetimibe to simvastatin in this population reduced the composite cardiovascular endpoint by a relative 6.4 percent over seven years. [2]

Patients with familial hypercholesterolemia, defined by the Dutch Lipid Clinic Network criteria as a score of 6 or above, often require ezetimibe as part of a combination regimen to reach LDL-C below 100 mg/dL or below 70 mg/dL in high-risk subgroups. [16] In these patients, statin monotherapy alone may reduce LDL by 50 percent but still leave absolute LDL far above target.

Statin-intolerant patients represent a third group. A 2022 meta-analysis published in the European Heart Journal covering 176,000 patient-years found that verified statin intolerance affects about 5 to 10 percent of treated patients. [17] In this group, ezetimibe monotherapy is a reasonable bridge or primary therapy, reducing LDL by 15 to 22 percent on average. [4]

The 10-year ASCVD risk calculated by the Pooled Cohort Equations (available at tools.acc.org) guides the threshold for initiating lipid-lowering therapy in primary prevention. Patients with a 10-year ASCVD risk of 7.5 percent or above and LDL-C of 70 mg/dL or above qualify for statin initiation; ezetimibe addition is considered when LDL remains above goal. [3]

Side Effects and Monitoring: What North Dakota Patients Should Know

Ezetimibe has a favorable tolerability profile. The most common adverse effects reported in clinical trials at rates above 2 percent include upper respiratory infection, diarrhea, arthralgia, and sinusitis, mostly at rates similar to placebo. [1] Myopathy is rare with ezetimibe monotherapy but may increase slightly when combined with statins, so providers typically check creatine kinase and liver function tests at baseline and again at 6 to 12 weeks after initiation.

No dose adjustment is needed for renal impairment. Mild to moderate hepatic impairment requires caution; ezetimibe is not recommended in patients with moderate or severe hepatic impairment due to unknown exposure levels. [1]

Drug interactions are limited. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption; spacing dosing by at least two hours resolves this interaction. Cyclosporine significantly increases ezetimibe plasma levels, so transplant patients need monitoring. [1]

The FDA label recommends baseline lipid panel before initiation and follow-up fasting lipid panel at 4 to 12 weeks after starting to confirm LDL-C response. [1] If LDL-C does not fall by at least 15 percent, adherence and drug interactions should be reviewed before escalating to a PCSK9 inhibitor such as evolocumab or alirocumab.

Cost Comparison: Ezetimibe vs. Alternatives in North Dakota

When a patient cannot reach LDL-C goals on a statin alone, the next-step options and their approximate North Dakota cash prices in 2026 are:

Generic ezetimibe 10 mg: approximately $15 per month cash. [6]

Colesevelam (Welchol) 625 mg: approximately $80 to $120 per month cash for the generic, which remains expensive relative to ezetimibe.

Evolocumab (Repatha) 140 mg biweekly injection: list price near $7,200 per year, though Amgen's patient assistance program can reduce this to $0 for qualifying patients. [18]

Alirocumab (Praluent) 75 mg biweekly injection: similar list price to Repatha, with Sanofi's patient assistance available.

Bempedoic acid (Nexletol) 180 mg: approximately $350 per month list, with generic entry not expected before 2027.

For the average North Dakota patient who needs modest additional LDL-C lowering (15 to 20 percent) on top of statin therapy, generic ezetimibe at $15 per month represents the most cost-efficient step before escalating to injectable PCSK9 inhibitors. The ACC/AHA writing committee explicitly placed ezetimibe before PCSK9 inhibitors in the treatment algorithm for this reason. [3]

How to Get the Lowest Ezetimibe Price in North Dakota: Step by Step

1. Ask your prescriber to write for "generic ezetimibe 10 mg" explicitly. Some pharmacy systems default to brand Zetia if the script is ambiguous.

2. Run the prescription through GoodRx, Blink Health, or the NeedyMeds drug pricing tool before paying. Prices change monthly. [6]

3. Compare at least two pharmacies. Walmart Pharmacy in Bismarck and Fargo consistently prices generic ezetimibe at or below $15 for 30 tablets.

4. If you are on North Dakota Medicaid and ezetimibe is non-covered, ask your cardiologist or primary care provider to document medical necessity and submit a prior authorization request citing the ACC/AHA guideline recommendation. [3]

5. If your commercial insurance places ezetimibe on Tier 3 or Tier 4, request a tier exception. Your prescriber's office can submit documentation of your LDL-C history and cardiovascular risk to support the exception.

6. If cost remains a barrier, ask your HealthRX provider whether a North Dakota-licensed 503A pharmacy with a compounding program is appropriate for your clinical situation.

7. Medicare Part D beneficiaries should use the Medicare Plan Finder at medicare.gov to identify which 2026 Part D plans in North Dakota cover generic ezetimibe on Tier 2 or lower before the annual open enrollment deadline.